1Jonas JB, Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol,2001,131:468-471.
2Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol, 2003, 121: 57-61.
3Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol, 2004, 122: 1131-1136.
4Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina,2000, 20:244-250.
5McCuen BW Ⅱ, Bessler M, Tano Y, et al. The lack of toxicity of intravitreal administered triamcinolone acetonide. Am J Ophthalmol, 1981, 91:785-788.
6Bailey TA, Kanuga N, Romero IA, et al. Oxidative stress affects junctional integrity of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci, 2004, 45:675-684.
7Dunn KC, Aotaki-Keen AE, Putkey FR, et al. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res, 1996, 62:155-169.
8Mahon GJ, Anderson HR, Gardiner TA, et al. Chloroquine causes lysosomal dysfunction in neural retina and RPE:implication for retinopathy. Cur Eye Res, 2004, 28:277-284.
9Yeung CK, Chan KP, Chan CK, et al. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells:comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol, 2004, 48:236-242.
10Yeung CK, Chan KP, Chiang SWY, et al. The toxic and stress response of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone.Invest Ophthalmol Vis Sci, 2003, 44:5293-5300.
1WETTERQVIST C, WONG D, WILLIAMS R, et al. Tamponade effi-ciency of perfluorohexyloctane and silicone oil solutions in a model eyechamber[ J].Br J Ophthalmol, 2004, 88(5) : 692 - 696.
2WONG D, VAN MEURS J C,STAPPLER T, et al. A pilot studyon the use of a perfluorohexyloctane/ silicone oil solution as a heav-ier than water internal tamponade agent [ J ].Br J Ophthalmol,2005, 89(6) : 662 -665.
3SANDNER D, ENGELMANN K. First experiences with high -density silicone oil ( Densiron) as an intraocular tamponade incomplex retinal detachment[ J].Graefes Arch Clin Exp Ophthal-mol, 2006, 244(5) : 609 -619.
4AVITABILE T’BONFIGLIO V,BUCC0LIER0 D, et al. Heavyversus standard silicone oil in the management of retinal detach-ment with macular hole in myopic eyes [ J ].Retina, 2011,31(3): 540-546.
5ER H. Primary heavy silicone oil usage in inferior rfiegmatogenous ret-inal detachment[ J].Ophthalmologica, 2010 , 224(2) : 122 -125.
6METE M,PAROUNI B, MAGGIO E, et al. 1000 cSt silicone oilvs heavy silicone oil as intraocular tamponade in retinal detachmentassociated to myopic macular hole [ J ].Graefes Arch Clin ExpOphthalmol, 2011,249(6) : 821 -826.
7HEIM ANN H. Alternative indications for the use of heavy siliconeoil tamponades[ J].Klin Monbl Augenheilkd, 2009, 226(9):713 -717.
8STAPPLER T, HEIMANN H,GIBRAN S K, et al. Densiron -68heavy silicone oil in cases of PVR. Anatomic and functional out-comes[J].Ophthalmologe, 2009, 106(4) : 320 -326.
9RIZZO S,GENOVESI EBERT F,VENTO A, et al. A new heavysilicone oil ( HWS 46 - 3000) used as a prolonged internal tam-ponade agent in complicated vitreoretinal surgery : a pilot study[J].Retina, 2007,27(5): 613 -620.
10WONG D,KUMAR I,QUAH S A,et al. Comparison of postoper-ative intraocular pressure in patients with Densiron - 68 vs conven-tional silicone oil: a case - control study[ J].Eye (Lond),2009,23(1) : 190-194.
